J

Jon M. Wigginton

Bristol-Myers Squibb (United States)

Publishes on Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses. 162 papers and 34.1k citations.

PubIndex Score96Top 4% · seniorHow it's scored

162Publications

34.1kTotal Citations

First publication: 1988First senior author: 1988

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune Responses Immune Cell Function and Interaction Neuroblastoma Research and Treatments

Top publicationsby citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012

Cited by 12.6k

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Jon M. Wigginton, S. Goldberg et al.|New England Journal of Medicine|2012

Cited by 8k

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Mario Sznol, Harriet M. Kluger et al.|New England Journal of Medicine|2013

Cited by 4.2k

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, F. Stephen Hodi, Mario Sznol et al.|Journal of Clinical Oncology|2014

Cited by 2.2k

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015

Cited by 1.2k